Eosinophilic asthma: From molecular signature to biologic treatment
Eosinophilic asthma, a common phenotype of severe asthma, is characterized by elevated blood eosinophil count (BEC) and is often associated with poor outcomes. At the Annual Scientific Meeting 2023 of the Hong Kong Thoracic Society and CHEST Delegation Hong Kong and Macau, Professor Ratko Djukanović of University of Southampton, UK, and Professor Kian-Fan Chung of Imperial College London, UK, shared insights into the molecular signature of eosinophilic asthma and discussed clinical evidence supporting the efficacy of add-on biologic treatments, such as mepolizumab, for severe eosinophilic asthma (SEA) and other airway disorders.

New Molecule

2 New

New Indication

5 New

New Presentation

1 New

Color 1
Color 2
Exclusive offer for doctors
Register for a 澳洲幸运10 account and receive free medical publications worth $768 a year.
Already a member? Sign in